SG11202110829YA - Stat degraders and uses thereof - Google Patents

Stat degraders and uses thereof

Info

Publication number
SG11202110829YA
SG11202110829YA SG11202110829YA SG11202110829YA SG11202110829YA SG 11202110829Y A SG11202110829Y A SG 11202110829YA SG 11202110829Y A SG11202110829Y A SG 11202110829YA SG 11202110829Y A SG11202110829Y A SG 11202110829YA SG 11202110829Y A SG11202110829Y A SG 11202110829YA
Authority
SG
Singapore
Prior art keywords
degraders
stat
stat degraders
Prior art date
Application number
SG11202110829YA
Other languages
English (en)
Inventor
Nello Mainolfi
Nan Ji
Bin Yang
Yi Zhang
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of SG11202110829YA publication Critical patent/SG11202110829YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11202110829YA 2019-04-05 2020-04-06 Stat degraders and uses thereof SG11202110829YA (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201962830095P 2019-04-05 2019-04-05
US201962833331P 2019-04-12 2019-04-12
US201962855259P 2019-05-31 2019-05-31
US201962860512P 2019-06-12 2019-06-12
US201962875362P 2019-07-17 2019-07-17
US201962877051P 2019-07-22 2019-07-22
US201962887872P 2019-08-16 2019-08-16
US201962926127P 2019-10-25 2019-10-25
US201962932957P 2019-11-08 2019-11-08
US201962944810P 2019-12-06 2019-12-06
US201962947310P 2019-12-12 2019-12-12
US201962949053P 2019-12-17 2019-12-17
US202062967921P 2020-01-30 2020-01-30
PCT/US2020/026869 WO2020206424A1 (en) 2019-04-05 2020-04-06 Stat degraders and uses thereof

Publications (1)

Publication Number Publication Date
SG11202110829YA true SG11202110829YA (en) 2021-10-28

Family

ID=72667015

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202110829YA SG11202110829YA (en) 2019-04-05 2020-04-06 Stat degraders and uses thereof

Country Status (15)

Country Link
US (3) US11485750B1 (ko)
EP (1) EP3946360A4 (ko)
JP (1) JP2022527114A (ko)
KR (1) KR20220006139A (ko)
CN (1) CN113939300A (ko)
AU (1) AU2020253633A1 (ko)
BR (1) BR112021019748A2 (ko)
CA (1) CA3135802A1 (ko)
CO (1) CO2021013339A2 (ko)
IL (1) IL286969A (ko)
MA (1) MA55565A (ko)
MX (1) MX2021012216A (ko)
SG (1) SG11202110829YA (ko)
TW (1) TW202106676A (ko)
WO (1) WO2020206424A1 (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202106676A (zh) 2019-04-05 2021-02-16 美商凱麥拉醫療公司 Stat降解劑及其用途
JP7424115B2 (ja) 2019-06-26 2024-01-30 住友化学株式会社 エステル化合物の製造方法
MX2022011437A (es) * 2020-03-17 2022-10-03 Kymera Therapeutics Inc Degradadores de transductores de se?al y activadores de la transcripcion (stat) y usos de los mismos.
US20230159573A1 (en) * 2020-03-26 2023-05-25 The Regents Of The University Of Michigan Small molecule stat protein degraders
US11988649B2 (en) * 2020-10-06 2024-05-21 Board Of Regents, The University Of Texas System On-line suppressor
UY39671A (es) 2021-03-15 2022-10-31 Novartis Ag Derivados de pirazolopiridina y sus usos.
TW202322799A (zh) * 2021-10-06 2023-06-16 美商Ｃ４醫藥公司 冠狀病毒非結構性蛋白3降解化合物
CA3236262A1 (en) * 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof
WO2023107706A1 (en) * 2021-12-11 2023-06-15 Kymera Therapeutics, Inc. Stat3 degraders and uses thereof
WO2023192960A1 (en) * 2022-03-31 2023-10-05 Recludix Pharma, Inc. Stat modulators and uses thereof
WO2023250058A1 (en) * 2022-06-22 2023-12-28 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2024064080A1 (en) * 2022-09-19 2024-03-28 Kymera Therapeutics, Inc. Stat6 degraders and uses thereof

Family Cites Families (181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5360811A (en) 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
JP3545461B2 (ja) 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
TR200400105T4 (tr) 1999-12-10 2004-02-23 Prizer Products Inc. Pirrolo [2,3-d] pirimidin bileşikleri
DE10002509A1 (de) 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
ATE297395T1 (de) 2000-02-28 2005-06-15 Sugen Inc 3-(pyrolyllacton)-2-indolinon verbindungen zur verwendung als kinase-hemmstoffe
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002020740A2 (en) 2000-09-08 2002-03-14 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
WO2002078617A2 (en) 2001-03-28 2002-10-10 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
US7071189B2 (en) 2001-04-27 2006-07-04 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
BRPI0313733A8 (pt) 2002-08-14 2016-08-16 Atugen Ag Uso da proteína n beta cinase
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
MXPA05012799A (es) 2003-05-30 2006-02-22 Gemin X Biotechnologies Inc Compuestos triheterociclicos, composiciones y metodos para tratar cancer o enfermedades virales.
WO2005007623A2 (en) 2003-07-03 2005-01-27 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
EP1701941B1 (en) 2003-12-11 2012-05-30 Board of Regents, The University of Texas System Compounds for treatment of cell proliferative diseases
JP4398263B2 (ja) 2004-01-13 2010-01-13 富士通株式会社 経路設計方法
US7436318B2 (en) 2004-04-19 2008-10-14 Atg Designworks, Llc Self contained device for displaying electronic information
EP1761540B1 (en) 2004-05-13 2016-09-28 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US20060005147A1 (en) 2004-06-30 2006-01-05 Hammack Jason L Methods and systems for controlling the display of maps aboard an aircraft
US20070010428A1 (en) 2004-09-03 2007-01-11 Mcmurray John S Inhibitors of signal transduction and activator of transcription 3
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2591948C (en) 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
CN101511179A (zh) 2005-02-25 2009-08-19 密执安州立大学董事会 Stat3的小分子抑制剂及其用途
EP2343320B1 (en) 2005-03-25 2017-10-25 GITR, Inc. Anti-gitr antibodies and uses thereof
TWI337608B (en) 2005-05-12 2011-02-21 Abbott Lab Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US20080139456A1 (en) 2005-09-30 2008-06-12 Burke Terrence R Macrocyclic Sh2 Domain Binding Inhibitors
KR101504994B1 (ko) 2005-10-07 2015-03-23 엑셀리시스, 인코포레이티드 포스파티딜이노시톨 3-키나아제 억제제 및 이의 사용 방법
CA2625219A1 (en) 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
EP1951684B1 (en) 2005-11-01 2016-07-13 TargeGen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
ES2611588T3 (es) 2005-12-13 2017-05-09 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
PL1966130T3 (pl) 2005-12-23 2014-05-30 Zealand Pharma As Zmodyfikowane związki mimetyczne lizyny
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PT2024372E (pt) 2006-04-26 2010-09-16 Hoffmann La Roche Derivado de tieno[3,2-d]pirimidina útil como inibidor de pi3k
US7960434B2 (en) 2006-05-19 2011-06-14 University Of South Florida Small molecule inhibitors of STAT3 with anti-tumor activity
CN102887900B (zh) 2006-09-22 2015-04-29 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
UA95978C2 (ru) 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
WO2008067270A1 (en) 2006-11-27 2008-06-05 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Macrocyclic grb2 sh2 domain-binding inhibitors
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
WO2008156644A2 (en) 2007-06-14 2008-12-24 Frank David A Stat modulators
JP5932217B2 (ja) 2007-07-12 2016-06-08 ジーアイティーアール， インコーポレイテッド Ｇｉｔｒ結合分子を使用する併用療法
WO2009032338A1 (en) 2007-09-09 2009-03-12 University Of Florida Research Foundation Apratoxin therapeutic agents: mechanism and methods of treatment
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
SG191660A1 (en) 2008-03-11 2013-07-31 Incyte Corp Azetidine and cyclobutane derivatives as jak inhibitors
EP2291187B1 (en) 2008-04-24 2018-08-15 Newlink Genetics Corporation Ido inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110033922A (ko) 2008-07-08 2011-04-01 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 전사의 신호 변환자 및 활성제（ｓｔａｔｓ）의 증식 및 활성화의 신규한 억제제
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010077589A2 (en) 2008-12-08 2010-07-08 The Regents Of The University Of Michigan Office Of Technology Transfer Stat3 inhibitors and therapeutic methods using the same
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
US8921037B2 (en) 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
US8841257B2 (en) 2009-04-10 2014-09-23 Board Of Regents, The University Of Texas System Inhibitors of STAT3 and uses thereof
CA2758916A1 (en) 2009-04-15 2010-10-21 Pui-Kai Li Curcumin analogs as dual jak2/stat3 inhibitors and methods of making and using the same
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme ANTI-GITRANT ANTIBODIES
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
JP2013512248A (ja) 2009-11-24 2013-04-11 ジ・オハイオ・ステート・ユニバーシティ 転写因子阻害剤および関連する組成物、製剤および方法
BR112012013717B1 (pt) 2009-12-10 2020-01-28 Hoffmann La Roche anticorpos de ligação ao csf-1r humano, composição farmacêutica e usos do anticorpo
US8445517B2 (en) 2009-12-11 2013-05-21 Dana-Farber Cancer Institute Stat modulators
US8796320B2 (en) 2009-12-28 2014-08-05 General Incorporated Association Pharma Valley Project Supporting Organization 1,3,4-Oxadiazole-2-carboxamide compound
HUE045487T2 (hu) 2010-03-04 2019-12-30 Macrogenics Inc B7-H3-ra reaktív antitestek, immunológiailag aktív fragmenseik és alkalmazásaik
KR101647871B1 (ko) 2010-03-05 2016-08-11 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
KR101656548B1 (ko) 2010-03-05 2016-09-09 에프. 호프만-라 로슈 아게 인간 ｃｓｆ-1ｒ에 대한 항체 및 이의 용도
ES2706412T3 (es) 2010-05-04 2019-03-28 Five Prime Therapeutics Inc Anticuerpos que se unen a CSF1R
CA2813571A1 (en) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
CN103153335A (zh) 2010-06-30 2013-06-12 布兰代斯大学 小分子靶定的蛋白质降解
CN103608010A (zh) 2010-08-02 2014-02-26 中央佛罗里达大学研究基金公司 作为stat蛋白的抑制剂的取代的2-羟基-4-(2-(苯基磺酰氨基)乙酰氨基)苯甲酸类似物
PL2614082T3 (pl) 2010-09-09 2019-02-28 Pfizer Inc. Cząsteczki wiążące 4-1BB
CN103502275A (zh) 2010-12-07 2014-01-08 耶鲁大学 融合蛋白的小分子疏水性标记和引起的其降解
WO2012078982A2 (en) 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
DK2649086T3 (en) 2010-12-09 2017-09-18 Univ Pennsylvania USING CHEMICAL ANTIGEN RECEPTOR-MODIFIED T-CELLS TO TREAT CANCER
WO2012097351A1 (en) 2011-01-14 2012-07-19 The Ohio State University Research Foundation Materials and methods to inhibit multiple myeloma cancer cells
WO2012142615A2 (en) 2011-04-14 2012-10-18 Board Of Regents, The University Of Texas System Auranofin and auranofin analogs useful to treat proliferative disease and disorders
NO2694640T3 (ko) 2011-04-15 2018-03-17
MX338353B (es) 2011-04-20 2016-04-13 Medimmune Llc Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
JP6138813B2 (ja) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体及びその使用
WO2013087699A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
EP3608317A1 (en) 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
BR112014028013A2 (pt) 2012-05-11 2018-02-27 Five Prime Therapeutics Inc métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea
EP2854819B1 (en) 2012-05-25 2020-01-15 The Governing Council of the University of Toronto Salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and medical use thereof
WO2013187965A1 (en) 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP2015527351A (ja) 2012-08-16 2015-09-17 オハイオ・ステイト・イノベーション・ファウンデーション Ｓｔａｔ３阻害剤およびその抗癌的使用
CA2882804A1 (en) 2012-08-31 2014-03-06 Brian Wong Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
US9422331B2 (en) 2012-09-19 2016-08-23 Hoffmann-La Roche Inc. 2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014070859A1 (en) 2012-10-30 2014-05-08 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
WO2014153495A2 (en) 2013-03-22 2014-09-25 University Of Hawaii Novel stat3 inhibitors
WO2014205416A1 (en) 2013-06-20 2014-12-24 University Of Hawaii Novel sesquiterpenoid stat3 inhibitors
US10053431B2 (en) 2013-11-18 2018-08-21 Hoffmann-La Roche Inc. Tetrahydro-benzodiazepinones
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
KR102320082B1 (ko) 2014-04-14 2021-10-29 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
KR101697062B1 (ko) 2014-08-26 2017-01-18 한국생명공학연구원 물에 대한 용해도가 개선된 신규 제라닐 프라보노이드 유도체, 이의 제조 방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 약학적 조성물
KR20160066490A (ko) 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
EP3256470B1 (en) 2014-12-23 2023-07-26 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016115455A2 (en) 2015-01-15 2016-07-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 6-aryl-7-substituted-3-(1h-pyrazol-5-yl)-7h-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines as inhibitors of the stat3 pathway with anti-proliferative activity
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11352351B2 (en) 2015-01-20 2022-06-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
AU2016213972B2 (en) 2015-02-05 2020-07-09 Tyrnovo Ltd. Combinations of IRS/Stat3 dual modulators and anti-cancer agents for treating cancer
MX2017011919A (es) 2015-03-18 2018-05-22 Arvinas Inc Compuestos y metodos para la degradacion mejorada de proteinas especificas.
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3302572B8 (en) 2015-06-04 2021-03-24 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
SE539204C2 (en) 2015-06-05 2017-05-09 Glactone Pharma Dev Ab Ether analogues of galiellalactone
EP3302482A4 (en) 2015-06-05 2018-12-19 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
CN105085620B (zh) 2015-06-25 2018-05-08 中山大学附属第一医院 一种靶向泛素化降解Smad3的化合物
WO2017007612A1 (en) * 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
BR112017028394A2 (pt) 2015-07-10 2018-08-28 Arvinas Inc composto, composição, e, métodos para induzir a degradação de uma proteína-alvo em uma célula e para tratar um estado doente ou uma condição doente.
US20170037004A1 (en) 2015-07-13 2017-02-09 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN
CA2996318C (en) 2015-09-18 2023-10-10 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
WO2017079267A1 (en) 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
WO2017117473A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
WO2017117474A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
EP3429996A4 (en) 2016-03-16 2020-02-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. SMALL MOLECULES DIRECTED AGAINST CEREBLON TO IMPROVE THE FUNCTION OF T EFFECTOR LYMPHOCYTES
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
BR112018070549A2 (pt) 2016-04-06 2019-02-12 The Regents Of The University Of Michigan degradantes de proteína mdm2
EP3440082A1 (en) 2016-04-06 2019-02-13 The Regents of The University of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
PL3458101T3 (pl) 2016-05-20 2021-05-31 F. Hoffmann-La Roche Ag Koniugaty PROTAC-przeciwciało i sposoby ich stosowania
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
US10975055B2 (en) 2016-11-22 2021-04-13 Dana-Farber Cancer Institute, Inc. Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
SE540295C2 (en) 2016-12-05 2018-05-29 Glactone Pharma Dev Ab Sulfonamide analogues of galiellalactone
CN111356456A (zh) 2017-01-23 2020-06-30 夏威夷大学 2-芳基磺酰胺基-iV-芳基乙酰胺衍生的Stat3抑制剂
KR20190116315A (ko) 2017-01-31 2019-10-14 아비나스 오퍼레이션스, 인코포레이티드 세레블론 리간드 및 이를 포함하는 이작용성 화합물
WO2018237026A1 (en) * 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
AU2018338314A1 (en) 2017-09-22 2020-04-09 Kymera Therapeutics, Inc Protein degraders and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
JP2021508703A (ja) 2017-12-26 2021-03-11 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
US11802132B2 (en) 2018-02-23 2023-10-31 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
WO2020010210A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2019389174A1 (en) 2018-11-30 2021-07-01 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP3947403A1 (en) * 2019-03-29 2022-02-09 The Regents Of The University Of Michigan Stat3 protein degraders
TW202106676A (zh) 2019-04-05 2021-02-16 美商凱麥拉醫療公司 Stat降解劑及其用途
JP2022538192A (ja) 2019-06-28 2022-08-31 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびその使用
WO2020264490A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20220281831A1 (en) 2019-07-15 2022-09-08 Kymera Therapeutics, Inc. Fused-glutarimide crbn ligands and uses thereof
WO2021011634A1 (en) 2019-07-15 2021-01-21 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2021011871A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20230219945A1 (en) 2019-12-17 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021127283A2 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021158634A1 (en) 2020-02-03 2021-08-12 Kymera Therapeutics, Inc. Irak degraders and uses thereof

Also Published As

Publication number Publication date
US11746120B2 (en) 2023-09-05
WO2020206424A1 (en) 2020-10-08
US11485750B1 (en) 2022-11-01
TW202106676A (zh) 2021-02-16
MX2021012216A (es) 2022-01-24
US20230120381A1 (en) 2023-04-20
MA55565A (fr) 2022-02-09
EP3946360A4 (en) 2023-05-10
JP2022527114A (ja) 2022-05-30
CA3135802A1 (en) 2020-10-08
CO2021013339A2 (es) 2022-01-17
EP3946360A1 (en) 2022-02-09
AU2020253633A1 (en) 2021-11-04
US20230084113A1 (en) 2023-03-16
BR112021019748A2 (pt) 2021-12-07
IL286969A (en) 2021-12-01
KR20220006139A (ko) 2022-01-14
CN113939300A (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
IL286969A (en) Stat joints and their use
IL289267A (en) Iraq joints and their uses
IL283471A (en) Iraq joints and their uses
IL275649A (en) IRAK joints and used in them
IL273432A (en) Protein compounds and their uses
EP3817822A4 (en) PROTEIN DEGRADANTS AND USES THEREOF
EP3737666A4 (en) PROTEIN DEGRADANTS AND USES THEREOF
EP4076520A4 (en) IRAQ DEGRADERS AND USES THEREOF
EP4076536A4 (en) IRAQ DEGRADATION AGENTS AND THEIR USES
EP3752504A4 (en) COMPOUNDS DEGRADING THE IRAQ AND USES OF THESE LATEST
IL285178A (en) compounds and their use
EP4076448A4 (en) FLUOROALKYLATED OXADIAZOLES AND THEIR USES
EP4076524A4 (en) IRAQ DEGRADERS AND USES THEREOF
EP3717079A4 (en) MASK DEVICES AND METHODS
EP4081308A4 (en) SMARCA DEGRADERS AND USES THEREOF
IL285177A (en) compounds and their use
EP4072591A4 (en) IRAQ DEGRADER AND USES THEREOF
ZA202105847B (en) Mtroc modulators and uses thereof
SG11202107498VA (en) Haloallylamine compounds and application thereof
IL286497A (en) compounds and their use
IL277502A (en) Compounds and uses for them
IL291499A (en) Azaquinoline compounds and their uses
IL284764A (en) compounds and their uses
IL279483A (en) Cyanotriazole compounds and their uses
EP4121055A4 (en) STAT DEGRADATION AGENTS AND THEIR USES